CARD15 and toll-like receptors: The link with Crohn's disease

Digestive and Liver Disease

Volumn 35, Issue 11, 2003, Pages 753-757

  Caprilli, Renzo ^a   Guagnozzi, D ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; CARD15 PROTEIN, HUMAN; CARRIER PROTEIN; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN; SIGNAL PEPTIDE;

ALLELE; CHROMOSOME 16; CROHN DISEASE; EDITORIAL; ENTEROBACTERIACEAE; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; PATHOGENESIS; PROTEIN EXPRESSION; RACE DIFFERENCE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; REVIEW;

CARRIER PROTEINS; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE GLYCOPROTEINS; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS; VARIATION (GENETICS);

EID: 1542494185     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00461-4     Document Type: Article

References (30)

1. Abreu MT. The pathogenesis of inflammatory bowel disease: trasnlational implications for clinicians. Curr Gastroenterol Rep 2002;4:481-9.
2. Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP. The genetics of inflammatory bowel disease. Aliment Pharmacol Ther 2001;15:731-48.
3. Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3.
4. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cèzard JP, Belaiche J, et al. Association NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
5. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
6. Hampe J, Cuthbert A, Croucher PJP, Muddassar MM, Mascheretti S, Fisher S, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-8.
7. Colombel JF. The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice? Clin Gastroenterol Hepatol 2003;1:5-9.
8. Inoue N, Tamura K, Kinouchi Y, Fukuda Y, Takahashi S, Ogura Y, et al. Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology 2002;123:86-91.
9. Sugimura M, Kinouchi Y, Takahashi S, Aihara H, Takagi S, Negoro K, et al. CARD15/NOD2 mutational analysis in Japanese patients with Crohn's disease. Clin Genet 2003;63:160-2.
10. Bonen DK, Nicolae DL, Moran T, Turkyilmaz MA, Ramos R, Kzaraliukas R, et al. Racial differences in NOD2 variation: characterization of NOD2 in African-Americans with Crohn's disease. Gastroenterology 2002;122:A-29.
11. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-66.
12. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122:867-74.
13. Lesage S, Zouali H, Cèzard JP, Colombel JF, Belaiche J, Almer S. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70:845-57.
14. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr EI, Yafi FA, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001;49:777-82.
15. Vermeire S, Louis E, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, et al. NOD2/CARD15 does not influence response to Infliximab in Crohn's disease. Gastroenterology 2002;123:106-11.
16. Mascheretti S, Hampe J, Croucher PJ, Nikolaus S, Andus T, Schubert S, et al. Response to Infliximab treatment in Crohn's disease is not associated with mutations in CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002;12:509-15.
17. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. NOD2, a NOD1/APAF-1 family member that is restricted to monocytes and activates NF-kB. J Biol Chem 2001;276:4812-8.
18. Girardin SE, Sansonetti PJ, Philpott DJ. Intracellular vs extracellular recognition of pathogens in mammal and flies. Trends Microbiol 2002;10:193-9.
19. Cho JH. The NOD2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease. Inflamm Bowel Dis 2001;7:271-5.
20. Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity 2001;15:5-14.
21. Rosenstiel P, Fantini M, Brautigam K, Kuhbacher T, Waetzig GH, Seegert D, et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003;124:1001-9.
22. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormik BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 2003;124:993-1000.
23. Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, et al. CARD15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut 2003;52:840-6.
24. Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, et al. Crohn's disease-associated NOD2 variants share a sgnaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 2003;124:140-6.
25. McGovern DPB, Van Heel DA, Ahmad T, Jewell DP. NOD2 (CARD15), the first susceptibility gene for Crohn's disease. Gut 2001;49:752-4.
26. Wright SD. Toll, a new piece in the puzzle of innate immunity. J Exp Med 1999;189:605-9.
27. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000;406:782-7.
28. Cario E. Toll-like receptor and gastrointestinal disease: from bench to beside. Curr Opin Gastroenterol 2002;18:696-704.
29. Zhang G, Ghosh S. Toll-like receptor-mediated NFkB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001;107:13-9.
30. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7.